Search results for " intravenous"

showing 10 items of 331 documents

Is global elimination of HCV realistic?

2017

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of …

medicine.medical_specialtySustained Virologic ResponseHepatitis C virusCost-Benefit Analysismedicine.disease_causeGlobal HealthWorld Health OrganizationAntiviral AgentsWorld health03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansMass Screening030212 general & internal medicineDisease EradicationIntensive care medicineSubstance Abuse Intravenouslinkage to caredirect antiviral agentHepatologybusiness.industryscreeningIncidence (epidemiology)Hcv clearancevirus diseasesHepatologyPatient Acceptance of Health CareHepatitis Cdigestive system diseases030211 gastroenterology & hepatologybusinessPatient awarenessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study: Myocardial Dysfunction, Postoperative Neurocognitive Dysfunction, and 1 Year Foll…

2018

Background Remote ischemic preconditioning ( RIPC ) has been suggested to protect against certain forms of organ injury after cardiac surgery. Previously, we reported the main results of RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study, a multicenter trial randomizing 1403 cardiac surgery patients receiving either RIPC or sham‐ RIPC . Methods and Results In this follow‐up paper, we present 1‐year follow‐up of the composite primary end point and its individual components (all‐cause mortality, myocardial infarction, stroke and acute renal failure), in a sub‐group of patients, intraoperative myocardial dysfunction assessed by transesophageal echocardiography and the incidenc…

medicine.medical_specialtyTime FactorsMyocardial InfarctionNeurocognitive DisordersMyocardial Reperfusion InjuryNeuropsychological Tests030204 cardiovascular system & hematologyischemia/reperfusion injuryRisk Assessment03 medical and health sciencesCognition0302 clinical medicineDouble-Blind MethodRisk FactorsIschemiaGermanyMulticenter trialClinical StudiesClinical endpointHumansMedicineProspective Studies030212 general & internal medicineMyocardial infarctionCardiac Surgical ProceduresProspective cohort studyPropofolStrokeOriginal ResearchCardiovascular Surgerycardio‐vascular surgerybusiness.industryIncidenceProtective Factorsmedicine.diseaseSurgeryCardiac surgeryTreatment OutcomeIschemic Preconditioning MyocardialIschemic preconditioningremote ischemic preconditioningCardiology and Cardiovascular MedicinebusinessPropofolAnesthetics IntravenousEchocardiography Transesophagealmedicine.drug
researchProduct

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-i…

2022

Summary Background Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to assess optimised vancomycin dosing. We compared the efficacy of an optimised regimen to a standard regimen in infants with late onset sepsis that was known or suspected to be caused by Gram-positive microorganisms. Methods NeoVanc was an open-label, multicentre, phase 2b, parallel-group, randomised, non-inferiority trial comparing the efficacy and toxicity of an optimised regimen of vancomycin to a standard regimen in infants aged …

medicine.medical_specialtyTime FactorsPopulationEquivalence Trials as TopicLoading doseArticlelaw.inventionGram-positiveRandomized controlled triallawVancomycinIntensive careInternal medicineIntensive Care Units NeonatalSepsisDevelopmental and Educational PsychologyClinical endpointMedicineHumansDosingeducationInfusions Intravenouseducation.field_of_studybusiness.industryInfant NewbornInfantdosingUnited KingdomAnti-Bacterial AgentsEuropeRegimenTreatment OutcomeSpainRelative riskPediatrics Perinatology and Child Healthsepsibusiness
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.

2011

Purpose: This study evaluated the safety and effectiveness of long-term enzyme replacement therapy with idursulfase (recombinant human iduronate-2-sulfatase) in patients with Hunter syndrome. Methods: All 94 patients who completed a 53-week double-blinded study of idursulfase enrolled in this open-labeled extension study and received intravenous idursulfase at a dose of 0.5 mg/kg weekly for 2 years, and clinical outcomes and safety were assessed. Results: No change in percent predicted forced vital capacity was seen, but absolute forced vital capacity demonstrated sustained improvement and was increased 25.1% at the end of the study. Statistically significant increases in 6-minute walking t…

medicine.medical_specialtyVital capacityAdolescentIdursulfaseIduronate SulfatasePulmonary function testingInternal medicineMedicineHumansEnzyme Replacement TherapyMucopolysaccharidosis type IIAdverse effectChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IIbusiness.industryPercent Predicted Forced Vital CapacityHunter syndromeEnzyme replacement therapyOrgan Sizemedicine.diseaseSurgeryTreatment OutcomeLiverChild PreschoolbusinessSpleenmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Auditory cortical and hippocampal local-field potentials to frequency deviant tones in urethane-anesthetized rats: An unexpected role of the sound fr…

2015

Abstract The human brain can automatically detect auditory changes, as indexed by the mismatch negativity of event-related potentials. The mechanisms that underlie this response are poorly understood. We recorded primary auditory cortical and hippocampal (dentate gyrus, CA1) local-field potentials to serial tones in urethane-anesthetized rats. In an oddball condition, a rare (deviant) tone ( p  = 0.11) randomly replaced a repeated (standard) tone. The deviant tone was either lower (2200, 2700, 3200, 3700 Hz) or higher (4300, 4800, 5300, 5800 Hz) in frequency than the standard tone (4000 Hz). In an equiprobability control condition, all nine tones were presented at random ( p  = 0.11). Diffe…

medicine.medical_specialtyacoustic frequencyhippocampusMismatch negativityHippocampusLocal field potentialHippocampal formationAudiologyAuditory cortexUrethaneta3112Rats Sprague-DawleyTone (musical instrument)local-field potentialsprimary auditory cortexPhysiology (medical)medicineAnimalschange detectionta515Auditory CortexAnalysis of VarianceCommunicationAuditory maskingbusiness.industryGeneral NeuroscienceDentate gyrusRatsNeuropsychology and Physiological PsychologyAcoustic StimulationAuditory PerceptionEvoked Potentials AuditorybusinessPsychologyAnesthetics IntravenousPsychoacousticsInternational Journal of Psychophysiology
researchProduct

Vascular atherosclerotic disease: evaluation of the whole-blood filterability and red cell membrane microrheological pattern after intravenous admini…

1990

SummaryA study was carried out in 10 patients with vascular atherosclerotic disease to investigate the effects of a single dose of 300 mg pentoxifylline, given by intravenous infusion over 30 minutes, on various macrorheological and nzicrorheological parameters. Measurements were made at baseline, at the end of the intravenous infusion and again 30 minutes later of whole-blood filterability, erythrocyte membrane fluidity (using pyrene as probe) and transverse fluidity gradient (using fluorescent fatty acids as probes). The results showed that there was a significant variation in whole-blood filterability and the red cell membrane fluidity gradient after pentoxifylline. No difference, howeve…

medicine.medical_specialtybusiness.industryArteriosclerosisMembrane FluidityErythrocyte MembraneAtherosclerotic diseaseGeneral MedicinePharmacologyMiddle AgedBlood ViscosityRed cell membraneSurgeryPentoxifyllineErythrocyte membraneErythrocyte DeformabilityInjections IntravenousmedicineMembrane fluidityHumansPentoxifyllinebusinessRheologymedicine.drugWhole bloodAgedCurrent medical research and opinion
researchProduct

Effects of retinotoxic drugs on rats heterozygotic for recessive retinitis pigmentosa

1971

medicine.medical_specialtybusiness.industryIodoacetatesRats Inbred Strainsmedicine.diseaseRetinaSensory SystemsRatsFluoridesOphthalmologyEndocrinologyInternal medicineInjections IntravenousRetinitis pigmentosaElectroretinographymedicineAnimalsCholinesterasesbusinessRetinitis PigmentosaVision Research
researchProduct

Absorption of drugs from the bladder and intravesical chemotherapy

1976

medicine.medical_specialtybusiness.industryUrologyUrinary BladderUrologyAntineoplastic AgentsPharmaceutical PreparationsUrinary Bladder NeoplasmsInjections IntravenousAnimalsHumansMedicineRabbitsIntravesical chemotherapybusinessAbsorption (electromagnetic radiation)ThiotepaUrological Research
researchProduct

Myogenic effects enhance norepinephrine constriction: Inhibition by nitric oxide and felodipine

1998

Myogenic effects enhance norepinephrine constriction: Inhibition by nitric oxide and felodipine. Myogenic, pressure-induced vasoconstriction may amplify the effects of circulating vasoconstrictors. Through intravital microscopy in cremaster arterioles (31 to 115 μm diameter), the relative contribution of myogenic responses (MR) to norepinephrine (NE)-induced constriction and the inhibitor potency of nitric oxide (NO) or a Ca2+ entry blocker (CEB), felodipine (F), were examined. In 24 anesthetized hamsters, a vessel occluder was placed around the aorta to control cremaster vessel inflow pressure (IP). NE infusion increased blood pressure (by 50 ± 2mm Hg) and induced significant constriction …

medicine.medical_specialtyendotheliumVasodilator AgentsmicrocirculationMyogenic mechanismBayliss effectBlood PressureNitric OxideNitroarginineMuscle Smooth VascularConstrictionNitric oxideMicrocirculationNorepinephrine (medication)Norepinephrinechemistry.chemical_compoundCricetinaeInternal medicineintravital microscopymedicineAnimalsVasoconstrictor AgentsBayliss effectAorta AbdominalcremasterFelodipineCapillariesArteriolesEndocrinologychemistryFelodipineNephrologyAnesthesiacalcium entry blockerInjections Intravenouscardiovascular systemmedicine.symptomVasoconstrictionmedicine.drugKidney International
researchProduct